{"product_id":"defining-optimal-immunotherapies-for-type-1-diabetes-isbn-9780470723258","title":"Defining Optimal Immunotherapies for Type 1 Diabetes","description":"\u003cul\u003e \u003cli\u003eThis book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).\u003c\/li\u003e \u003cli\u003eBrings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.\u003c\/li\u003e \u003cli\u003eThe book integrates information from human and animal studies.\u003c\/li\u003e \u003cli\u003eThe book considers T1D within the broader context of autoimmune disease.\u003c\/li\u003e \u003cli\u003eThe format contains several discussions, which address specific questions and provides guidelines for future strategies and solutions for discovering a cure.\u003c\/li\u003e \u003c\/ul\u003e  \u003cb\u003e1. Michael Rutter\u003c\/b\u003e  \u003cp\u003eIntroduction: whither gene–environment interactions?\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Rudolf Uher\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interaction: overcoming methodological challenges\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Marco Battaglia, Cecilia Marino, Michel Maziade, Massimo Molteni\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eFrancesca D’Amato\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interaction and behavioural disorders: a developmental perspective based on endophenotypes\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Naomi R. Wray, William L. Coventry, Michael R. James, Grant W. Montgomery, Lindon J. Eaves\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eNicholas G. Martin\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eUse of monozygotic twins to investigate the relationship between 5HTTLPR genotype, depression and stressful life events: an application of Item Response Theory\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAppendix\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral discussion I\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Harold Snieder, Xiaoling Wang, Vasiliki Lagou, Brenda W. J. H. Penninx, Harriëtte Riese\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eCatharina A. Hartman\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRole of gene–stress interactions in gene-finding studies\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Kenneth A. Dodge\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePractice and public policy in the era of gene–environment interactions\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Kristi B. Adamo\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eFrédérique Tesson\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interaction and the metabolic syndrome\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral discussion II\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Stephen P. Robertson\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eRichie Poulton\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLongitudinal studies of gene–environment interaction in common diseases—good value for money?\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Kee-Seng Chia\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interactions in breast cancer\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. Malak Kotb, Nourtan\u003c\/b\u003e \u003cb\u003eAbdeltawab\u003c\/b\u003e\u003cb\u003e, Ramy Aziz, Sarah Rowe, Robert W. Williams\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eLu Lu\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eUnbiased forward genetics and systems biology approaches to understanding how gene–environment interactions work to predict susceptibility and outcomes of infections\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Steven R. Kleeberger\u003c\/b\u003e \u003cb\u003eand\u003c\/b\u003e \u003cb\u003eHye-Youn Cho\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interactions in environmental lung diseases\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral discussion III\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Fernando D. Martinez\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGene–environment interaction in complex diseases: asthma as an illustrative case\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13\u003c\/b\u003e. \u003cb\u003eMichael Rutter\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConclusions: taking stock and looking ahead\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGlossary\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex of contributors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSubject index\u003c\/b\u003e\u003c\/p\u003e  The \u003cstrong\u003eNovartis Foundation\u003c\/strong\u003e is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.  \u003cp\u003eType 1 diabetes (T1D) can be managed by administration of insulin, but the search continues for a more permanent cure.  Hopes were high in the early 1990s, when the similarity between mouse and human MHC class II diabetes susceptibility genes had been discovered, and a cure seemed at hand via modulating interactions between CD4+ T cells and such MHC molecules. Unfortunately pathogenesis of T1D is much more complex, polygenic, dependent on disease penetrance on multiple environmental factors, and likely to involve the participation of CD4+, CD8+ and B lymphocytes. Additionally, islet β-cell destruction might involve mechanisms that differ among individuals.\u003c\/p\u003e \u003cp\u003eSince T1D is an autoimmune disease, a likely strategy in this search for a cure seems to be modulation of the immune system. This book therefore brings together contributions from leaders in the arena of clinical immunotherapy, not limited to the diabetes field.\u003c\/p\u003e \u003cp\u003eTopics discussed focus on the following questions:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eWhen and where does the co-ordination of the immune responses leading to islet destruction take place?\u003c\/li\u003e \u003cli\u003eWhat are the crucial histopathological features of human diabetes, and are these accurately reflected in mouse models?\u003c\/li\u003e \u003cli\u003eCan we define the functional features of pathogenic response, and can we assess whether these allow prediction of T1D development on an individual basis?\u003c\/li\u003e \u003cli\u003eCan we delineate a roadmap for successfully prioritizing and accelerating immunotherapeutics in T1D?\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDefining optimal immunotherapies for type 1 diabetes\u003c\/i\u003e offers a comprehensive and up-to-date account of immunological strategies for preventing or treating T1D, and will be of particular interest to diabetologists and endocrinologists, both clinicians and researchers, as well as to immunologists and molecular or cell biologists and drug discovery scientists. The book also considers T1D within the broader context of autoimmune disease, and is therefore of interest to clinicians and researchers working on any such disease.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989034942693,"sku":"NP9780470723258","price":211.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470723258.jpg?v=1761782526","url":"https:\/\/k12savings.com\/es\/products\/defining-optimal-immunotherapies-for-type-1-diabetes-isbn-9780470723258","provider":"K12savings","version":"1.0","type":"link"}